OfficeHours

AUGUST 20, 2023

Private equity involves investing capital directly into private businesses that are not publicly traded on stock exchanges (that would be a hedge fund). Once improved, the exit can then take place, usually in the form of another sale or an Initial Public Offering (IPO), both of which are usually under the advice of an investment bank.

Private Equity 130

Private Equity Equities Investment Banking Finance 130

Cooley M&A

SEPTEMBER 16, 2022

There are compelling rationales for adopting a dual-class structure, but even proponents of the structure generally acknowledge that these benefits are significantly mitigated once the dual-class shares are out of the hands of the founders and/or pre-IPO stockholders. Voting agreements in public M&A transactions.

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Software Equity Group

OCTOBER 22, 2024

WATCH NOW : Craft a Winning Pricing Strategy to Maximize ARR Growth and Valuation Net Retention in Public Software Companies: Insights from the SEG SaaS Index We recently began tracking net retention information in our SEG SaaS Index , which tracks the performance of 120+ publicly traded software companies.

Valuation 52

Valuation Investors IT Management 52

Cooley M&A

JANUARY 20, 2022

For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses. closing friction. billion (including earnouts). And, by some measures, almost 75% of private?target

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

Despite the mixed success of these campaigns, their prevalence has led public company boards to focus on activist preparedness –particularly as private equity sponsors increasingly team up with, or quickly follow, activists advocating for a sale.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Focus Investment Banking

FEBRUARY 11, 2025

Traditional terminal exit routes for private equity-backed companies are to larger strategic acquirers (often public companies) and IPOs, where a private company becomes publicly traded. It is also likely that IPOs will come to PPM, perhaps first to those specialties with the largest assets (e.g.,

Private Equity 52

Private Equity Healthcare Equities Medical 52

Cooley M&A

JANUARY 22, 2025

By 2030, more than 190 commercial drugs will lose patent exclusivity , putting at risk $236 billion in Big Pharma sales. This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64